What is Biofrontera AG (BFFTF)?

Biofrontera AG (BFFTF) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of BFFTF?

The current price of BFFTF is $0.33. Prices are updated in real time on Stocks360.

What is BFFTF's price-to-earnings (PE) ratio?

BFFTF's trailing twelve-month PE ratio is -0.03, based on current price and earnings per share data available on Stocks360.

What is BFFTF's market capitalization?

BFFTF's market capitalization is $19,346,895.00, placing it in the small-cap tier.

Biofrontera AG (BFFTF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$0.33

Market Cap

$19.35M

PE (TTM)

-0.03

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.59

Day Range

$0.33 – $1.08

52-wk Range

$0.33 – $22.68

Avg Volume

N/A

Volume

2.00K

Biofrontera AG (BFFTF) is a publicly traded company in the Healthcare sector. Latest price: $0.33. Market cap $19.35M. Trailing PE -0.03. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 13, 2023

EPS $-2.09 vs est. $-0.33

Missed by $1.75

Proprietary Signals

Signal snapshot temporarily unavailable.

About Biofrontera AG

Biofrontera AG operates as a biopharmaceutical enterprise, dedicated to the exploration, evolution, and commercialization of dermatological therapies. Its flagship offerings, Ameluz and the BF-RhodoLED lamp, are utilized for treating mild to moderate actinic keratoses on the face and scalp, managing field cancerization, and addressing life-threatening squamous cell carcinoma. The company is also advancing RhodoLED XL, intended for extensive interspersed lesions, and provides Belixos, an innovative cosmetic product designed for sensitive and irritated skin. Furthermore, Biofrontera develops Xepi, an agent targeting infections from antibiotic-resistant bacteria. The company primarily markets its solutions across the United States, Europe, and Israel, and maintains a collaborative and partnership agreement with Maruho Co., Ltd. Founded in 1997, Biofrontera AG's corporate headquarters are situated in Leverkusen, Germany.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.03×
P/S (TTM)	0.57×
P/B	0.11×
P/FCF (TTM)	-0.78×
EV / EBITDA	-1.31×
EV / Sales	0.71×
Earnings Yield	-3945.10%
Free Cash Flow Yield	-128.70%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$24.09M
Revenue (TTM)	$34.07M
Net Income (TTM)	-$763.26M
Free Cash Flow (TTM)	-$24.30M
Net Debt	$4.75M
Working Capital	$4.99M
Gross Margin	48.80%
Operating Margin	-66.56%
Net Margin	-59.09%
Return on Equity	-140.42%
Return on Invested Capital	-149.88%